Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CEMIPLIMAB-RWLC for Neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 33 adverse event reports in the FDA FAERS database where CEMIPLIMAB-RWLC was used for Neoplasm malignant.

Most Reported Side Effects for CEMIPLIMAB-RWLC

Side Effect Reports % Deaths Hosp.
Death 128 8.2% 126 13
Disease progression 101 6.5% 29 15
Fatigue 71 4.6% 10 19
Off label use 68 4.4% 12 12
Rash 64 4.1% 2 17
Dyspnoea 55 3.5% 12 25
Pyrexia 52 3.4% 8 41
Pruritus 44 2.8% 1 10
Asthenia 42 2.7% 16 23
Diarrhoea 42 2.7% 5 27
Myocarditis 42 2.7% 19 27
Interstitial lung disease 39 2.5% 3 24
Nausea 38 2.5% 12 26
Drug ineffective 34 2.2% 3 2
Pneumonitis 33 2.1% 3 18

Other Indications for CEMIPLIMAB-RWLC

Squamous cell carcinoma of skin (370) Product used for unknown indication (348) Squamous cell carcinoma (234) Non-small cell lung cancer (83) Cervix carcinoma recurrent (72) Cervix carcinoma (43) Basal cell carcinoma (42) Metastatic squamous cell carcinoma (42) Lung neoplasm malignant (34) Lung adenocarcinoma (32)

Other Drugs Used for Neoplasm malignant

PALBOCICLIB (1,996) CAPECITABINE (1,493) PEMBROLIZUMAB (1,135) PACLITAXEL (984) CARBOPLATIN (977) NIVOLUMAB (947) OXALIPLATIN (823) PAZOPANIB (716) CYCLOPHOSPHAMIDE (685) FLUOROURACIL (676)

Related Pages

CEMIPLIMAB-RWLC Full Profile All Neoplasm malignant Drugs CEMIPLIMAB-RWLC Demographics CEMIPLIMAB-RWLC Timeline